Biohaven Ltd. (BHVN)
NYSE: BHVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
BHVN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.80B
- EPS (TTM)
- -$4.56
- Dividend yield
- None
- 52-week range
- 7.48 – 18.57
- Day range
- 11.46 – 12.12
- Volume / Avg
- 2.70M / 2.62M
- Beta
- —
- Shares outstanding
- 151.04M
- Next earnings
- Nov 9, 2026
52-week range
BHVN stock today
On Oct 8, BHVN ended the session at $11.93, adding $0.05 (0.42%), versus the S&P 500's 0.47% decline. At this level, BHVN sits in the middle of its 52-week range of $7.48 to $18.57: 35.7% below the high, set on Oct 30, 2025 and 59.5% above the low. BHVN is up 5.7% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 22.2%.
Biohaven has posted a net loss over the last twelve months (EPS of -$4.56), so its P/E ratio is not meaningful. Biohaven's next earnings report is expected on Nov 9, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Biohaven
Company profileBiohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Vladimir Coric M.D.
- Headquarters
- New Haven, CT
- Employees
- 274
- IPO year
- 2022
- Website
- biohaven.com
Analyst forecast
ForecastConsensus (17 analysts)
buy
Avg. price target
$21.27+78.29%
- Strong buy 3
- Buy 9
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 9, 2026
BHVN news
All BHVN newsBiohaven peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GENBGenerate Biomedicines Inc. | 13.99 | +3.10% | $1.80B | vs BHVN |
| URGNUroGen Pharma Ltd. | 36.98 | -9.14% | $1.81B | vs BHVN |
| ZYMEZymeworks Inc. | 25.26 | -4.79% | $1.81B | vs BHVN |
| XNCRXencor Inc. | 24.50 | +0.99% | $1.82B | vs BHVN |
| TRVITrevi Therapeutics Inc. | 12.83 | -2.40% | $1.83B | vs BHVN |
| NUVBNuvation Bio Inc. Class A | 4.95 | +1.85% | $1.74B | vs BHVN |
| SEPNSepterna Inc. | 36.90 | +2.50% | $1.72B | vs BHVN |
| BRVEBraveheart Bio Inc. | 19.09 | +2.74% | $1.72B | vs BHVN |
Indexes, lists and sector
Biohaven stock FAQ
What is Biohaven's stock price today?
BHVN last traded at $11.93 as of Oct 8, 4:00 PM EDT, up 0.42% on the day. Prices are delayed at least 15 minutes.
When is Biohaven's next earnings date?
Biohaven is expected to report earnings on Monday, November 9, 2026.
Who is Biohaven's CEO?
Dr. Vladimir Coric M.D. is the chief executive officer of Biohaven Ltd., which has about 274 employees.
What is the BHVN 52-week high?
The 52-week high for BHVN is $18.57 and the 52-week low is $7.48. The stock is currently 35.7% below its high.